When was Veravas founded?

Veravas was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Veravas located?

Veravas is headquartered in Oakdale, United States.

How many employees does Veravas have?

As of Dec 31, 2018, the latest employee count at Veravas is 4.

Is Veravas a funded company?

Veravas is a funded company, having raised a total of $25M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 01, 2019.

When was the latest funding round of Veravas?

Veravas' latest funding was a $***** Series A round on Mar 15, 2024, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $2.01B in funding in 2026 to date.

Where does Veravas rank among its competitors?

Veravas ranks 6th amongst 41 active competitors, of which 16 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was C₂N Diagnostics, which secured $10M in May, 2025.

Who are the top competitors of Veravas?

Veravas' top competitors include ADmit Therapeutics, C₂N Diagnostics and Amydis Diagnostics. Among them, C₂N Diagnostics secured the most recent funding round in May, 2025.

Veravas - 2026 Company Profile, Team, Funding & Competitors

Company Details

VERAVAS provides a platform to manage sample preparation and diagnostic samples. The proprietary technology VeraPrep which helps in optimizing the patient's samples and preparing it for the diagnostic process by eliminating biotin and multiple interference substances using nanobead technology. The processed samples are then analyzed using VeraTest platform which detects the biomarkers attached with the nanobeads to identify the type of diseases.

Website: veravas.com
Email ID: *****@veravas.com

Key Metrics

Founded Year

2017

Location

Oakdale, United States

Stage

Series A

Total Funding

$25M in 4 rounds

Latest Funding Round

Series A, Mar 15, 2024, $*****

Investors

SeedFunders

Ranked

6^th among 41 active competitors

Employee Count

4 as on Dec 31, 2018

Similar Companies

ADmit Therapeutics & 54 more

View Veravas' full profile

Veravas is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VERAVAS, INC CIN: 822849414 , United States, Active	Dec 31, 1999	-	4 (As on Nov 30, 2018)	-

Veravas has raised a total funding of $25M over 4 rounds. Its first funding round was on Oct 01, 2019. Veravas has 1 institutional investor.

Here is the list of recent funding rounds of Veravas:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 15, 2024	7511746	Series A	2847566	6169666	5378075	1338098
Mar 15, 2024	9000468	Conventional Debt	9296985	2875216	5170796	1954424
Feb 19, 2020	9356069	Seed	6065623	6978238	7656319	7331748

Access funding benchmarks and valuations. Sign up today!

View details of Veravas's funding rounds and investors

The founders of Veravas is John Forrest.

Here are the details of Veravas' key team members:

John Forrest: Founder and Executive Chairman of Veravas.

View details of Veravas's Founder profiles and Board Members

Veravas' employee count trend

Veravas has 4 employees as of Dec 18. Here is Veravas's employee count trend over the years:

Uncover Veravas' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Veravas include ADmit Therapeutics, C₂N Diagnostics and Amydis Diagnostics. Here is the list of Top 10 competitors of Veravas, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ADmit Therapeutics 2017, Barcelona (Spain), Series A	Provider of diagnostic services for early detection of Alzheimer's disease	$12.9M	Ship2B, Bstartup Banco Sabadell & 13 others	57/100
2nd	C₂N Diagnostics 2007, St. Louis (United States), Series B	Developer of diagnostics and therapies for Alzheimer's disease	$35M	Eisai, Samsung BioLogics & 6 others	56/100
3rd	Amydis Diagnostics 2013, San Diego (United States), Series A	Developer of diagnostics test for detection of Alzheimer's disease	$8.69M	NIA, JLABS & 3 others	52/100
4th	Todos Medical 2009, Rehovot (Israel), Public	Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders	-	Lincoln Park Capital, Yozma & 2 others	48/100
5th	DiamiR 2009, Monmouth Junction (United States), Funding Raised	Developer of minimally invasive diagnostic tests	-	NIA, HHS	47/100
6th	Veravas 2017, Oakdale (United States), Series A	Provider of platform to manage sample preparation and diagnostic solutions	$25M	SeedFunders	46/100
7th	ALZpath 2020, Carlsbad (United States), Seed	Developer of diagnostic solutions for Alzheimer's Disease	-	Alzheimer's Drug Discovery	42/100
8th	SYNAPS Dx 2016, Rockville (United States), Series A	Developer of a diagnostic test to detect Alzheimer's disease	$10M	Semler Scientific	35/100
9th	NeuroDex 2018, Natick (United States), Seed	Manufacturer of diagnostic tools for Alzheimer's disease	$1.36M	ICV, HHS	34/100
10th	Vivid Genomics 2018, San Diego (United States), Seed	Developer of diagnostic tests for neurodegenerative diseases	$20K	Ad Astra Ventures, Crescent Ridge & 2 others	34/100